메뉴 건너뛰기




Volumn 59, Issue 6, 2014, Pages 2403-2412

Is genotype 3 of the hepatitis C virus the new villain?

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; PEGINTERFERON LAMBDA; RIBAVIRIN; TELAPREVIR;

EID: 84901620722     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26905     Document Type: Review
Times cited : (119)

References (74)
  • 1
    • 84876149257 scopus 로고    scopus 로고
    • Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence
    • Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
    • (2013) Hepatology , vol.57 , pp. 1333-1342
    • Mohd Hanafiah, K.1    Groeger, J.2    Flaxman, A.D.3    Wiersma, S.T.4
  • 2
    • 84866898184 scopus 로고    scopus 로고
    • Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study
    • Lee M-H, Yang H-I, Lu S-N, Jen C-L, You S-L, Wang L-Y, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-477.
    • (2012) J Infect Dis , vol.206 , pp. 469-477
    • Lee, M.-H.1    Yang, H.-I.2    Lu, S.-N.3    Jen, C.-L.4    You, S.-L.5    Wang, L.-Y.6
  • 3
    • 25844523297 scopus 로고    scopus 로고
    • Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
    • Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-973.
    • (2005) Hepatology , vol.42 , pp. 962-973
    • Simmonds, P.1    Bukh, J.2    Combet, C.3    Deleage, G.4    Enomoto, N.5    Feinstone, S.6
  • 4
    • 46049084854 scopus 로고    scopus 로고
    • A new genotype of hepatitis C virus originating from Central Africa
    • Murphy DG, Chamberland J, Dandavino R, Sablon E. A new genotype of hepatitis C virus originating from Central Africa. Hepatology 2007;46:623A.
    • (2007) Hepatology , vol.46
    • Murphy, D.G.1    Chamberland, J.2    Dandavino, R.3    Sablon, E.4
  • 5
    • 79958717571 scopus 로고    scopus 로고
    • The global health burden of hepatitis C virus infection
    • Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011;31(Suppl 2):1-3.
    • (2011) Liver Int , vol.31 , Issue.2 SUPPL. , pp. 1-3
    • Negro, F.1    Alberti, A.2
  • 6
    • 77950624760 scopus 로고    scopus 로고
    • The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report
    • Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30:342-355.
    • (2010) Liver Int , vol.30 , pp. 342-355
    • Antaki, N.1    Craxi, A.2    Kamal, S.3    Moucari, R.4    Van der Merwe, S.5    Haffar, S.6
  • 7
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    • Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
    • (2004) Ann Intern Med , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette Jr, H.2    Morgan, T.R.3    Balan, V.4    Diago, M.5    Marcellin, P.6
  • 9
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
    • (2001) Lancet , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3    Rustgi, V.K.4    Shiffman, M.5    Reindollar, R.6
  • 12
    • 36348950196 scopus 로고    scopus 로고
    • Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study
    • Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007;46:1350-1356.
    • (2007) Hepatology , vol.46 , pp. 1350-1356
    • Bruno, S.1    Crosignani, A.2    Maisonneuve, P.3    Rossi, S.4    Silini, E.5    Mondelli, M.U.6
  • 14
    • 14544284040 scopus 로고    scopus 로고
    • Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients
    • Rumi MG, De Filippi F, La Vecchia C, Donato MF, Gallus S, Del Ninno E, et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005;54:402-406.
    • (2005) Gut , vol.54 , pp. 402-406
    • Rumi, M.G.1    De Filippi, F.2    La Vecchia, C.3    Donato, M.F.4    Gallus, S.5    Del Ninno, E.6
  • 15
    • 84856474979 scopus 로고    scopus 로고
    • The interaction of metabolic factors with HCV infection: does it matter?
    • Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 2012;56(Suppl 1):S56-S65.
    • (2012) J Hepatol , vol.56 , Issue.1 SUPPL.
    • Bugianesi, E.1    Salamone, F.2    Negro, F.3
  • 16
    • 0020362076 scopus 로고
    • Histologic observations in human hepatitis non-A, non-B
    • Dienes HP, Popper H, Arnold W, Lobeck H. Histologic observations in human hepatitis non-A, non-B. Hepatology 1982;2:562-571.
    • (1982) Hepatology , vol.2 , pp. 562-571
    • Dienes, H.P.1    Popper, H.2    Arnold, W.3    Lobeck, H.4
  • 17
    • 0021783064 scopus 로고
    • Wiese M, Haupt R. [Histomorphologic picture of chronic non-A
    • Wiese M, Haupt R. [Histomorphologic picture of chronic non-A, non-B hepatitis.] Dtsch Z Verdau Stoffwechselkr 1985;45:101-110.
    • (1985) non-B hepatitis.] Dtsch Z Verdau Stoffwechselkr , vol.45 , pp. 101-110
  • 18
    • 33646529840 scopus 로고    scopus 로고
    • Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data
    • Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-1642.
    • (2006) Gastroenterology , vol.130 , pp. 1636-1642
    • Leandro, G.1    Mangia, A.2    Hui, J.3    Fabris, P.4    Rubbia-Brandt, L.5    Colloredo, G.6
  • 19
    • 21044456174 scopus 로고    scopus 로고
    • Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C
    • Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-1008.
    • (2005) Gut , vol.54 , pp. 1003-1008
    • Fartoux, L.1    Poujol-Robert, A.2    Guechot, J.3    Wendum, D.4    Poupon, R.5    Serfaty, L.6
  • 20
    • 0034987263 scopus 로고    scopus 로고
    • Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
    • Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
    • (2001) Hepatology , vol.33 , pp. 1358-1364
    • Adinolfi, L.E.1    Gambardella, M.2    Andreana, A.3    Tripodi, M.F.4    Utili, R.5    Ruggiero, G.6
  • 21
  • 22
    • 0036830436 scopus 로고    scopus 로고
    • Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response
    • Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36:1266-1272.
    • (2002) Hepatology , vol.36 , pp. 1266-1272
    • Kumar, D.1    Farrell, G.C.2    Fung, C.3    George, J.4
  • 23
    • 0038122773 scopus 로고    scopus 로고
    • Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C
    • Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
    • (2003) Hepatology , vol.38 , pp. 75-85
    • Poynard, T.1    Ratziu, V.2    McHutchison, J.3    Manns, M.4    Goodman, Z.5    Zeuzem, S.6
  • 24
    • 34547097746 scopus 로고    scopus 로고
    • Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress
    • Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 2007;81:8122-8130.
    • (2007) J Virol , vol.81 , pp. 8122-8130
    • Waris, G.1    Felmlee, D.J.2    Negro, F.3    Siddiqui, A.4
  • 25
    • 84880290533 scopus 로고    scopus 로고
    • Hepatitis C virus infection activates an innate pathway involving IKK-alpha in lipogenesis and viral assembly
    • Li Q, Pene V, Krishnamurthy S, Cha H, Liang TJ. Hepatitis C virus infection activates an innate pathway involving IKK-alpha in lipogenesis and viral assembly. Nat Med 2013;19:722-729.
    • (2013) Nat Med , vol.19 , pp. 722-729
    • Li, Q.1    Pene, V.2    Krishnamurthy, S.3    Cha, H.4    Liang, T.J.5
  • 27
    • 70350746698 scopus 로고    scopus 로고
    • Changes in the expression of cholesterol metabolism-associated genes in HCV-infected liver: a novel target for therapy?
    • Nakamuta M, Yada R, Fujino T, Yada M, Higuchi N, Tanaka M, et al. Changes in the expression of cholesterol metabolism-associated genes in HCV-infected liver: a novel target for therapy? Int J Mol Med 2009;24:825-828.
    • (2009) Int J Mol Med , vol.24 , pp. 825-828
    • Nakamuta, M.1    Yada, R.2    Fujino, T.3    Yada, M.4    Higuchi, N.5    Tanaka, M.6
  • 28
    • 33644882808 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection
    • De Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, et al. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006;23:107-114.
    • (2006) Aliment Pharmacol Ther , vol.23 , pp. 107-114
    • De Gottardi, A.1    Pazienza, V.2    Pugnale, P.3    Bruttin, F.4    Rubbia-Brandt, L.5    Juge-Aubry, C.E.6
  • 29
    • 23044450214 scopus 로고    scopus 로고
    • Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver
    • Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, Nomura S, et al. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 2005;50:1361-1371.
    • (2005) Dig Dis Sci , vol.50 , pp. 1361-1371
    • Yamaguchi, A.1    Tazuma, S.2    Nishioka, T.3    Ohishi, W.4    Hyogo, H.5    Nomura, S.6
  • 30
    • 14944374003 scopus 로고    scopus 로고
    • Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection
    • Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005;128:334-342.
    • (2005) Gastroenterology , vol.128 , pp. 334-342
    • Dharancy, S.1    Malapel, M.2    Perlemuter, G.3    Roskams, T.4    Cheng, Y.5    Dubuquoy, L.6
  • 31
    • 18244365866 scopus 로고    scopus 로고
    • Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis
    • Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185-194.
    • (2002) FASEB J , vol.16 , pp. 185-194
    • Perlemuter, G.1    Sabile, A.2    Letteron, P.3    Vona, G.4    Topilco, A.5    Chretien, Y.6
  • 32
    • 33646382082 scopus 로고    scopus 로고
    • Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis
    • Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006;130:1661-1669.
    • (2006) Gastroenterology , vol.130 , pp. 1661-1669
    • Mirandola, S.1    Realdon, S.2    Iqbal, J.3    Gerotto, M.4    Dal Pero, F.5    Bortoletto, G.6
  • 34
    • 70350044610 scopus 로고    scopus 로고
    • Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up
    • Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009;50:1030-1037.
    • (2009) Hepatology , vol.50 , pp. 1030-1037
    • Corey, K.E.1    Kane, E.2    Munroe, C.3    Barlow, L.L.4    Zheng, H.5    Chung, R.T.6
  • 35
    • 70349247875 scopus 로고    scopus 로고
    • Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C
    • Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009;50:697-706.
    • (2009) Hepatology , vol.50 , pp. 697-706
    • Vanni, E.1    Abate, M.L.2    Gentilcore, E.3    Hickman, I.4    Gambino, R.5    Cassader, M.6
  • 36
    • 82755163055 scopus 로고    scopus 로고
    • Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis
    • Harris C, Herker E, Farese RV Jr, Ott M. Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis. J Biol Chem 2011;286:42615-42625.
    • (2011) J Biol Chem , vol.286 , pp. 42615-42625
    • Harris, C.1    Herker, E.2    Farese Jr, R.V.3    Ott, M.4
  • 38
    • 79959537058 scopus 로고    scopus 로고
    • Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets
    • Clement S, Peyrou M, Sanchez-Pareja A, Bourgoin L, Ramadori P, Suter D, et al. Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets. Hepatology 2011;54:38-49.
    • (2011) Hepatology , vol.54 , pp. 38-49
    • Clement, S.1    Peyrou, M.2    Sanchez-Pareja, A.3    Bourgoin, L.4    Ramadori, P.5    Suter, D.6
  • 39
    • 84882890676 scopus 로고    scopus 로고
    • PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism
    • Peyrou M, Clement S, Maier C, Bourgoin L, Branche E, Conzelmann S, et al. PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism. J Hepatol 2013;59:420-426.
    • (2013) J Hepatol , vol.59 , pp. 420-426
    • Peyrou, M.1    Clement, S.2    Maier, C.3    Bourgoin, L.4    Branche, E.5    Conzelmann, S.6
  • 41
    • 42949138790 scopus 로고    scopus 로고
    • Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors
    • Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134:1699-1714.
    • (2008) Gastroenterology , vol.134 , pp. 1699-1714
    • Missiha, S.B.1    Ostrowski, M.2    Heathcote, E.J.3
  • 42
    • 84856380143 scopus 로고    scopus 로고
    • IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes
    • Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012;55:384-394.
    • (2012) Hepatology , vol.55 , pp. 384-394
    • Bochud, P.Y.1    Bibert, S.2    Kutalik, Z.3    Patin, E.4    Guergnon, J.5    Nalpas, B.6
  • 43
    • 21344472982 scopus 로고    scopus 로고
    • Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C
    • Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71.
    • (2005) Hepatology , vol.42 , pp. 63-71
    • Hezode, C.1    Roudot-Thoraval, F.2    Nguyen, S.3    Grenard, P.4    Julien, B.5    Zafrani, E.S.6
  • 44
    • 69949182408 scopus 로고    scopus 로고
    • Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
    • Bochud P-Y, Cai T, Overbeck K, Bochud M, Dufour J-F, Müllhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655-666.
    • (2009) J Hepatol , vol.51 , pp. 655-666
    • Bochud, P.-Y.1    Cai, T.2    Overbeck, K.3    Bochud, M.4    Dufour, J.-F.5    Müllhaupt, B.6
  • 45
    • 80054085809 scopus 로고    scopus 로고
    • Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis
    • Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis. J Viral Hepatitis 2011;18:745-759.
    • (2011) J Viral Hepatitis , vol.18 , pp. 745-759
    • Probst, A.1    Dang, T.2    Bochud, M.3    Egger, M.4    Negro, F.5    Bochud, P.Y.6
  • 47
    • 77649134018 scopus 로고    scopus 로고
    • Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection
    • e921.
    • McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, Homan C, et al. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology 2010;138:922-931.e921.
    • (2010) Gastroenterology , vol.138 , pp. 922-931
    • McMahon, B.J.1    Bruden, D.2    Bruce, M.G.3    Livingston, S.4    Christensen, C.5    Homan, C.6
  • 49
    • 84860287080 scopus 로고    scopus 로고
    • Epidemiology of viral hepatitis and hepatocellular carcinoma
    • El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273 e1261.
    • (2012) Gastroenterology , vol.142
    • El-Serag, H.B.1
  • 50
    • 67349105629 scopus 로고    scopus 로고
    • Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis
    • Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009;50:1142-1154.
    • (2009) J Hepatol , vol.50 , pp. 1142-1154
    • Raimondi, S.1    Bruno, S.2    Mondelli, M.U.3    Maisonneuve, P.4
  • 51
    • 80052825683 scopus 로고    scopus 로고
    • HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
    • Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepatitis 2011;18:e516-e522.
    • (2011) J Viral Hepatitis , vol.18
    • Nkontchou, G.1    Ziol, M.2    Aout, M.3    Lhabadie, M.4    Baazia, Y.5    Mahmoudi, A.6
  • 52
    • 84871487025 scopus 로고    scopus 로고
    • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
    • van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
    • (2012) JAMA , vol.308 , pp. 2584-2593
    • van der Meer, A.J.1    Veldt, B.J.2    Feld, J.J.3    Wedemeyer, H.4    Dufour, J.F.5    Lammert, F.6
  • 53
    • 79952450963 scopus 로고    scopus 로고
    • Non-genomic loss of PTEN function in cancer: not in my genes
    • Leslie NR, Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci 2011;32:131-140.
    • (2011) Trends Pharmacol Sci , vol.32 , pp. 131-140
    • Leslie, N.R.1    Foti, M.2
  • 54
    • 0037054934 scopus 로고    scopus 로고
    • Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase
    • Rahman MA, Kyriazanos ID, Ono T, Yamanoi A, Kohno H, Tsuchiya M, et al. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer 2002;100:152-157.
    • (2002) Int J Cancer , vol.100 , pp. 152-157
    • Rahman, M.A.1    Kyriazanos, I.D.2    Ono, T.3    Yamanoi, A.4    Kohno, H.5    Tsuchiya, M.6
  • 55
    • 2442683905 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
    • Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-999.
    • (2004) J Hepatol , vol.40 , pp. 993-999
    • Zeuzem, S.1    Hultcrantz, R.2    Bourliere, M.3    Goeser, T.4    Marcellin, P.5    Sanchez-Tapias, J.6
  • 57
    • 34447318385 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
    • Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134.
    • (2007) N Engl J Med , vol.357 , pp. 124-134
    • Shiffman, M.L.1    Suter, F.2    Bacon, B.R.3    Nelson, D.4    Harley, H.5    Sola, R.6
  • 58
    • 47749115740 scopus 로고    scopus 로고
    • Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
    • Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008;28:397-404.
    • (2008) Aliment Pharmacol Ther , vol.28 , pp. 397-404
    • Andriulli, A.1    Mangia, A.2    Iacobellis, A.3    Ippolito, A.4    Leandro, G.5    Zeuzem, S.6
  • 59
    • 80052024078 scopus 로고    scopus 로고
    • Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future
    • Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011;54:789-800.
    • (2011) Hepatology , vol.54 , pp. 789-800
    • Di Martino, V.1    Richou, C.2    Cervoni, J.P.3    Sanchez-Tapias, J.M.4    Jensen, D.M.5    Mangia, A.6
  • 60
    • 84870533049 scopus 로고    scopus 로고
    • High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
    • Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56:2039-2050.
    • (2012) Hepatology , vol.56 , pp. 2039-2050
    • Marcellin, P.1    Cheinquer, H.2    Curescu, M.3    Dusheiko, G.M.4    Ferenci, P.5    Horban, A.6
  • 61
    • 80052116134 scopus 로고    scopus 로고
    • Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections
    • Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881-889 e881.
    • (2011) Gastroenterology , vol.141
    • Foster, G.R.1    Hezode, C.2    Bronowicki, J.P.3    Carosi, G.4    Weiland, O.5    Verlinden, L.6
  • 62
    • 84879159643 scopus 로고    scopus 로고
    • Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3
    • Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J Hepatol 2013;59:31-37.
    • (2013) J Hepatol , vol.59 , pp. 31-37
    • Silva, M.O.1    Treitel, M.2    Graham, D.J.3    Curry, S.4    Frontera, M.J.5    McMonagle, P.6
  • 63
    • 80052123459 scopus 로고    scopus 로고
    • Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses
    • Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011;141:1067-1079.
    • (2011) Gastroenterology , vol.141 , pp. 1067-1079
    • Gottwein, J.M.1    Scheel, T.K.2    Jensen, T.B.3    Ghanem, L.4    Bukh, J.5
  • 64
    • 79952296871 scopus 로고    scopus 로고
    • Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha
    • Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 2011;140:1032-1042.
    • (2011) Gastroenterology , vol.140 , pp. 1032-1042
    • Scheel, T.K.1    Gottwein, J.M.2    Mikkelsen, L.S.3    Jensen, T.B.4    Bukh, J.5
  • 65
    • 84884223989 scopus 로고    scopus 로고
    • Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 Study
    • Dore G, Lawitz E, Hézode C, Shafran S, Ramji A, Tatum H, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 Study. J Hepatol 2013;58(Suppl 1):S570.
    • (2013) J Hepatol , vol.58 , Issue.1 SUPPL.
    • Dore, G.1    Lawitz, E.2    Hézode, C.3    Shafran, S.4    Ramji, A.5    Tatum, H.6
  • 66
    • 77954646871 scopus 로고    scopus 로고
    • PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication
    • Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, et al. PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010;54:3187-3196.
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 3187-3196
    • Lam, A.M.1    Murakami, E.2    Espiritu, C.3    Steuer, H.M.4    Niu, C.5    Keilman, M.6
  • 69
    • 84901586415 scopus 로고    scopus 로고
    • EU Clinical Trials Register - VALENCE trial. Available at: accessed July 29
    • EU Clinical Trials Register - VALENCE trial. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001942-16/EE#A; accessed July 29, 2013.
    • (2013)
  • 70
    • 79960566304 scopus 로고    scopus 로고
    • Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3
    • Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol 2011;9:688-693.
    • (2011) Clin Gastroenterol Hepatol , vol.9 , pp. 688-693
    • Shah, S.R.1    Patel, K.2    Marcellin, P.3    Foster, G.R.4    Manns, M.5    Kottilil, S.6
  • 72
    • 36348981708 scopus 로고    scopus 로고
    • Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial
    • Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-981.
    • (2007) Hepatology , vol.46 , pp. 971-981
    • Jacobson, I.M.1    Brown Jr, R.S.2    Freilich, B.3    Afdhal, N.4    Kwo, P.Y.5    Santoro, J.6
  • 73
    • 84880304436 scopus 로고    scopus 로고
    • Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study
    • 309A.
    • Pawlotsky JM, Sarin SK, Foster G, Peng CY, Rasenack J, Flisiak R, et al. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study Hepatology 2012;56(Suppl):309A.
    • (2012) Hepatology , vol.56 , Issue.SUPPL.
    • Pawlotsky, J.M.1    Sarin, S.K.2    Foster, G.3    Peng, C.Y.4    Rasenack, J.5    Flisiak, R.6
  • 74
    • 84863710462 scopus 로고    scopus 로고
    • Peginterferon lambda-1a compared to peginterferon alfa-2a in treatment-naive patients with HCV genotypes 2 or 3: first SVR24 results from EMERGE phase IIB
    • Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, et al. Peginterferon lambda-1a compared to peginterferon alfa-2a in treatment-naive patients with HCV genotypes 2 or 3: first SVR24 results from EMERGE phase IIB. J Hepatol 2012;56(Suppl 1):S5-S6.
    • (2012) J Hepatol , vol.56 , Issue.1 SUPPL.
    • Zeuzem, S.1    Arora, S.2    Bacon, B.3    Box, T.4    Charlton, M.5    Diago, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.